If you have type 2 diabetes, your doctor may suggest Bydureon BCise (exenatide extended-release) as a treatment option. Along with other factors, you may have questions about possible side effects of ...
Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...
BYDUREON BCISE The expanded approval was based on data from a phase 3 study that evaluated exenatide extended-release in 82 patients aged 10 to 17 years with type 2 diabetes. The Food and Drug ...
Exenatide ext-rel 2mg; susp for SC inj; contains sucrose. <10yrs: not established. Give by SC inj in abdomen, thigh, or upper arm; rotate inj sites. Inject immediately after mixing. ≥10yrs: 2mg once ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s BYDUREON BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); ...
(Sharecast News) - AstraZeneca announced on Thursday that the European Commission (EC) has approved Bydureon BCise - exenatide 2mg prolonged-release suspension for injection in pre-filled pen - as a ...
Against the backdrop of challenges for its Type 2 diabetes Bydureon business, AstraZeneca has received some good news from the FDA. The U.S. regulatory agency green lit the therapy in children, making ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the Phase III pivotal trial (NCT01554618) showed AstraZeneca’s exenatide extended-release 2mg once weekly significantly reduced blood sugar—as ...
Byetta is a brand-name injection that’s prescribed for managing blood sugar levels in adults with type 2 diabetes. Byetta contains the active drug exenatide and belongs to the glucagon-like peptide-1 ...
BYDUREON BCise (exenatide extended-release) is the first once-weekly GLP-1 RA treatment option for pediatric patients with type 2 diabetes in the US AstraZeneca’s BYDUREON BCise ...
New formulation of once-weekly exenatide in an improved device provides significant HbA1c reduction with added benefit of weight loss Across two clinical trials, average HbA1c reductions of up to 1.4% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback